Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial - Burns, DK; Alexander, RC; Welsh-Bohmer, KA; Culp, M; Chiang, C; O'Neil, J; Evans, RM; Harrigan, P; Plassman, BL; Burke, JR; Wu, J; Lutz, MW; et al. (Lancet Neurology, 2021)